CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CDNA is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock shows a constructive technical uptrend, sentiment from options is mildly bullish, and the latest analyst action supports upside with a higher price target and Buy rating. With no recent negative news, no notable insider or hedge fund selling, and a positive long-term growth story tied to the Naveris acquisition, the setup is favorable for a long-term purchase at current levels.
CDNA is trading in a short-term bullish structure. Price is 23.64, essentially flat versus the prior close, but the broader setup is positive: SMA_5 > SMA_20 > SMA_200 indicates an established uptrend, and the MACD histogram is positive and expanding, which supports continued momentum. RSI_6 at 70.245 suggests the stock is near overbought territory, but not a clear reversal signal by itself. Key levels: pivot 22.81, resistance at 23.784 and 24.386, with support at 21.836 and 21.234. Overall trend is bullish, though near-term upside may be somewhat extended.
["BTIG raised its price target to $28 from $26 and reiterated a Buy rating.", "Analyst believes CareDx can exceed its 2027 long-range revenue target of $500M.", "Naveris acquisition could improve growth mix by shifting toward a faster-growing, higher-margin MRD business.", "No negative news in the recent week.", "No significant insider selling and hedge fund activity is neutral, not negative.", "Technical trend remains bullish with moving averages aligned upward."]
["No recent news catalysts in the past week, so there is no fresh event-driven momentum from news flow.", "RSI near 70 suggests the stock is somewhat extended in the short term.", "Implied volatility is very high, which often reflects elevated uncertainty around future movement.", "No strong bullish AI Stock Picker or SwingMax signal today.", "No recent congress trading data or notable political buying support."]
No reliable latest-quarter financial snapshot was available in the data, so a direct quarter-by-quarter growth assessment cannot be made from the provided figures. The only forward-looking financial context available is BTIG's view that CareDx is likely to outperform its 2027 revenue target of $500M, driven by core transplant business strength and the addition of the higher-growth Naveris business. The latest quarter season is not provided in the dataset.
Recent analyst trend is positive: BTIG raised its price target to $28 from $26 and kept a Buy rating on 2026-04-29. The note was constructive on the Q1 call and highlighted the Naveris acquisition as a strategic growth and margin improvement catalyst. Wall Street pros view: bullish due to improving growth prospects, better mix, and upside to long-term revenue goals. Cons view: the stock already has a favorable setup and no fresh data confirms accelerating fundamentals in the last reported quarter, so some of the good news may already be reflected in the price.
